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ABSTRACT
Prostate cancer remains the second leading cause of death in men. It is imperative 
to improve patient management in identifying bio-markers for personalized treatment. 
We demonstrated miR-15/miR-16 loss and miR-21 up-regulation and deregulation of 
their target genes, which represent a promising signature for ameliorating therapy 
assignment and risk assessment in prostate cancer.
DISCUSSION
“Molecular Structure of Nucleic Acids: A Structure 
for Deoxyribose Nucleic Acid” was an article published 
by Francis Crick and James D. Watson in the scientific 
journal Nature in 1953. This article was termed a “pearl” 
of science because it contains the answer to a fundamental 
mystery about life, how genetic instructions are held 
inside organisms and how they pass from generation to 
generation. The discovery of the DNA double helix made 
clear that genes are functional parts of biological systems. 
As consequence, we have assumed the postulate that DNA 
contained genes which are transcribed in mRNA and then 
translated into proteins. Proteins could control genes in 
feedback loops then they were considered the major actors 
in the living system theatre. Francis Crick and James D. 
Watson at that time did not know that their extraordinary 
discovery was only showing one face of the moon due to 
limitations of technology. In fact, years after the advent 
of high-resolution whole genome and transcriptome 
sequencing technologies showed that there exists a second 
intriguing face. Results demonstrated the existence of 
coding and non-coding genes showing that at least 90% 
of the genome is actively transcribed in non-coding 
RNAs whereas protein coding genes (mRNA) represent 
< 2% of total sequences[1]. According to knowledge 
acquired until now, -who knows in the near future-, non-
coding RNAs may be generally grouped into two major 
classes, small (18-200 nt) and long (200 nt to > 100Kb) 
RNAs based on transcript size[1]. Small RNAs include 
the well-documented microRNA (miRNA) gene family. 
Victor Ambros, Rosalind Lee and Rhonda Feinbaum 
discovered the first miRNA in 1993, lin-4, that was 
expressed in C. elegans[2]. In 2000, the small molecule 
lin-7 was discovered exhibiting silencing activity on lin-
41[3]. One year later, the large family of microRNA was 
studied in C. elegans, Drosophila and “Homo Sapiens”[4]. 
This scientific revolution produced the maximum effect 
when a non-coding RNA perturbation was associated with 
disease development in humans including cancer[1,5]. 
An article published by Croce et al. in 2005 reported that 
miR-15 and miR-16 deletion caused CLL development 
and progression[6]. In 2008, the same miR-15/miR-
16 cluster down-regulation was studied in solid tumors 
and was associated with prostate cancer progression[7]. 
Subsequently, several other articles demonstrated miR-
15 and miR-16 are tumor-suppressor miRNAs[8]. Many 
articles focusing on the deregulation of miRNAs in cancer 
were published in the following years to come. The 
Oncomir miR-21 has been thoroughly investigated[9]. 
In prostate cancer, miR-21 promotes hormone-dependent 
and hormone-independent growth[10]. Over the last few 
years many studies have been devoted to elucidating the 
aberrant molecular mechanisms involving miRNAs and 
their multiple mRNA targets. Since non-coding RNAs are 
abundant and extremely stable in biological fluids they 
represent a new source for the discovery of reliable and 
sensitive biomarkers for optimizing diagnosis, prognosis 
and therapy-sensitiveness prediction of advanced 
patients. In fact, programs for patient management and 
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risk assessment such as diagnostic screening, active 
surveillance protocols and clinical trials for new drug 
testing, are waiting for non-invasive tools and the best 
markers. In the era of personalized therapy, molecular 
markers are guiding the decision-making process 
regarding the best therapeutic treatment for approaching 
radical surgery and to select optimal sensitive-candidate-
patients, which are  the main goals. This is key in drawing 
the researchers’ and the clinical community’s attention. 
Up until today, we are obliged to consider and interpret 
a plethora of results and data produced in the last decade 
which have changed and renewed our point of view. 
DNA, non-coding RNA, mRNA and proteins act together 
in concert in a sophisticated equilibrium to maintain 
biological systems. In a pathological state, this equilibrium 
is destroyed and new aberrant networks are established. 
This is one of the reasons why the battle against cancer 
is still open. Thus, we have to approach cancer from a 
variety of sides in order to discover and block aberrant 
molecular mechanisms promoting cancer. Numerous 
genetic alterations have been associated with prostate 
cancer which remains one of the leading causes of death 
in men. Following the demonstration that miR-15 and 
miR-16 down-regulation was directly involved in prostate 
cancer progression, we embarked on discovering which 
multiple mechanisms could synergize and create the tumor 
phenotype[11]. We extended the study by demonstrating 
that an early K-RAS-modified tumor model assumed a 
metastatic phenotype after miR-15 and miR-16 down-
regulation. Although not frequently mutated in prostate 
cancer, RAS isoforms play a pivotal role in multiple 
pathways that have been implicated in tumorigenesis. 
Thus, the results showed that miR-15/miR-16 down-
regulation synergize with RAS activation in promoting 
tumor aggressiveness. On the other hand, RAS has been 
shown to promote prostate cancer progression by working 
synergistically with other pathways. In particular, a large 
body of literature indicated a collaboration between RAS 
and TGF-β, with a prominent role of RAS signaling 
in the conversion from anti- to pro-oncogenic TGF-β 
signaling. Hatley et al., showed that RAS aberrant 
cascade is reproduced by miR-21 over-expression. We 
revealed a simultaneous alteration of miR-15/miR-16 
down-regulation and miR-21 up-regulation in a consistent 
fraction of patients’ primary cells and tissues. Then, we 
studied the cross-talk of miR-15/miR-16 down-regulation 
and miR-21 up-regulation in cancer development. 
Increased miR-21 and loss of miR-15/miR-16 seem to 
Figure 1: Pro-metastasis aberrant circuit involving TGF-β, RAS, IHH and miRNA alterations. Genome representation 
following the international human sequencing consortium (2001). LINEs (long interspersed nuclear elements); SINEs (short interspersed 
nuclear elements). Cartoon representing the molecular mechanisms involved in bone metastasis dissemination. Transforming growth factor 
beta (TGF-β); Indian hedgehog (IHH); Runt-related transcription factor 2 (RUNX-2); Receptor activator of nuclear factor kappa-B ligand 
(RANKL); Interleukin 11 (IL-11); C-X-C chemokine receptor type 4 (CXCR-4); Connective Tissue Growth Factor (CTGF).
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particularly cooperate at the level of TGF-β signaling. 
Interestingly, miR-15 and miR-16 can target Activin RIIA, 
a receptor belonging to the TGF-β family triggered by 
Activin A and Nodal. The increased expression of Nodal 
reported in prostate cancer may therefore contribute to 
enhancing SMAD signaling after loss of miR-15 and miR-
16. In addition, miR-21 controls SMAD-7, an inhibitor 
of TGF-β pathway. We showed a new molecular circuit 
driven by miR-15, miR-16 and miR-21 alterations, 
resulting in aberrant TGF-β signaling. In the bone 
marrow microenvironment, mesenchymal stem cells 
and metastatic prostate cancer cells can produce TGF-β, 
which is reported to play a significant role in prostate 
cancer progression, as indicated by its release in sera 
of advanced patients[12] and by  the TGF-β inhibitors’ 
ability in preventing the formation of bone metastasis 
in preclinical models[13]. Several bone metastasis-
associated genes induced by TGF-β were revealed to be 
an indirect effect, such as RANKL, RUNX2, CXCR-4, 
CTGF and IL-11. It has been reported that TGF-β can 
post-transcriptionally regulate IHH ligand, a key gene in 
bone metastasis formation. We demonstrated that miR-15 
and miR-16 can directly control IHH gene. Our results 
showed a pro-metastasis aberrant circuit involving TGF-β, 
RAS, IHH and miRNA alterations. There are many TGF-β 
signaling antagonist agents under development at both the 
pre-clinical and clinical stages. In patients with CRPC 
(castration-resistant prostate cancer) and bone metastases, 
Denosumab, targeting RANKL ligand, reduced the 
risk of skeletal complications. Increasing synthetic Hh 
antagonists are being reported in the literature. Several 
of these compounds are now in clinical trials, including 
GDC-0449. Our data demonstrate the function of miR-
15, miR-16 and miR-21 together with the deregulation of 
direct and indirect gene targets in bone metastases (Figure 
1) and may acquire importance as biomarkers for active 
surveillance protocols and in therapy decision-making for 
patient treatment.   
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